Paper42100932
Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.
Foulser PFG and 11 others. Inflamm Bowel Dis, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort. Papers, record 42100932. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42100932
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colitis, Ulcerative | Major topic |
| Crohn Disease | Major topic |
| Adolescent | |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Young Adult | |
| Adrenal Cortex Hormones | |
| Age of Onset | |
| Cohort Studies | |
| Colectomy | |
| Follow-Up Studies | |
| Phenotype | |
| Prognosis | |
| Tumor Necrosis Factor-alpha | |
| United Kingdom |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| National Institute of Health Research Imperial Biomedical Research Centre based at Imperial College London and Imperial College Healthcare NHS Trust | PubMed | |||
| MR/Z504002/1 | Medical Research Council Clinician Scientist Fellowship | PubMed | ||
| MR/Z504002/1 | National Institute of Health Research Imperial Biomedical Research Centre | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39096528 | Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients. | Inflamm Bowel Dis | 2025 | https://conductscience.org/library/papers/39096528 | PubMed |
| 2 | 32097073 | Global ageing: successes, challenges and opportunities. | Br J Hosp Med (Lond) | 2020 | https://conductscience.org/library/papers/32097073 | PubMed |
| 3 | 25267328 | Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. | Am J Gastroenterol | 2014 | https://conductscience.org/library/papers/25267328 | PubMed |
| 4 | 36098310 | Is it time to include older adults in inflammatory bowel disease trials? A call for action. | Lancet Healthy Longev | 2022 | https://conductscience.org/library/papers/36098310 | PubMed |
| 5 | 26928965 | Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. | J Crohns Colitis | 2016 | https://conductscience.org/library/papers/26928965 | PubMed |
| 6 | 34481954 | Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. | Clin Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/34481954 | PubMed |
| 7 | 32142940 | Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. | Clin Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32142940 | PubMed |
| 8 | 33234880 | High Rates of Mortality in Geriatric Patients Admitted for Inflammatory Bowel Disease Management. | J Clin Gastroenterol | 2022 | https://conductscience.org/library/papers/33234880 | PubMed |
| 9 | 36681569 | Management of inflammatory bowel disease in the elderly: A review. | Dig Liver Dis | 2023 | https://conductscience.org/library/papers/36681569 | PubMed |
| 10 | 29050646 | Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. | Lancet | 2017 | https://conductscience.org/library/papers/29050646 | PubMed |
| 11 | 22605668 | Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. | Inflamm Bowel Dis | 2013 | https://conductscience.org/library/papers/22605668 | PubMed |
| 12 | 20951835 | Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. | Clin Gastroenterol Hepatol | 2011 | https://conductscience.org/library/papers/20951835 | PubMed |
| 13 | 30891808 | Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. | Aliment Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30891808 | PubMed |
| 14 | 22890223 | Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. | Am J Gastroenterol | 2012 | https://conductscience.org/library/papers/22890223 | PubMed |
| 15 | 40089251 | Risk of Age-related and Disease-related Complications and Mortality in Elderly-onset Inflammatory Bowel Disease: A Population-based Study. | Clin Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/40089251 | PubMed |
| 16 | 39209204 | Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study. | Clin Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39209204 | PubMed |
| 17 | 29102619 | Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. | Gastroenterology | 2018 | https://conductscience.org/library/papers/29102619 | PubMed |
| 18 | 30616024 | Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. | Clin Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/30616024 | PubMed |
| 19 | 37078376 | Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study. | Aliment Pharmacol Ther | 2023 | https://conductscience.org/library/papers/37078376 | PubMed |
| 20 | 26978725 | Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. | Inflamm Bowel Dis | 2016 | https://conductscience.org/library/papers/26978725 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42100932
GET https://conductscience.org/api/papers/v1/42100932/references?page=2